long intergenic non-protein coding RNA 1806Genealiases: []
Q-omics provides the consensus-scored LINC01806 profile across patient tissues and cancer cell-line models. LINC01806 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LINC01806 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LINC01806 RNA expression shows 14,260 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, THCA, and THYM as cancer lineages where LINC01806 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01806 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01806 survival associations across molecular data types. LINC01806 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01806 RNA expression–survival associations across cancer types. High LINC01806 expression shows unfavorable associations in UVM and LIHC, but favorable associations in SKCM, LUSC, LUAD and SARC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LINC01806 RNA expression.
This table summarizes LINC01806 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01806. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01806 shows lower tumor expression in THCA, KIRC, KICH, KIRP and LUAD and higher tumor expression in HNSC. The THCA box plot shows higher LINC01806 RNA expression in normal versus tumor tissue (log2 FC = −1.443, t-test p < 0.001).
This table shows molecular features associated with LINC01806 in patient tissues and cancer cell lines. In patient samples, LINC01806 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
